IV Ketamine vs Spravato

IV Ketamine vs Spravato: Which Treatment Is Right for You?

When you first start researching specialized depression treatment, two names come up repeatedly: IV ketamine and Spravato. Understanding IV ketamine vs Spravato is one of the most important steps a patient can take before scheduling a clinical evaluation, because these are two distinct treatments with different regulatory statuses, different delivery methods, different insurance implications, and different clinical profiles. Getting that distinction right matters for your health decisions and for your wallet.

Allay Health and Wellness offers both IV ketamine infusion therapy and Spravato (esketamine) from its Palm Beach Gardens clinic, serving patients from across Palm Beach County, Broward County, and South Florida. This guide walks through every meaningful dimension of IV ketamine vs Spravato so that you arrive at your first consultation with an accurate clinical picture, not a marketing one.

What IV Ketamine and Spravato Actually Are

Before going deeper into IV ketamine vs Spravato, it helps to understand what each compound is at a chemical level.

Ketamine is a medication that has been FDA-approved as an anesthetic since the 1970s. It exists as a mixture of two mirror-image molecules: R-ketamine and S-ketamine (also called esketamine). Spravato contains only esketamine, the S-enantiomer of ketamine, delivered as a nasal spray. It is a pharmaceutical formulation developed specifically for the psychiatric indications it carries today. IV ketamine infusion therapy uses the full racemic ketamine mixture, administered intravenously at sub-anesthetic doses in a supervised clinical setting.

Both act on the brain’s glutamate system through NMDA receptor modulation, which is the fundamental mechanism that distinguishes both of them from conventional antidepressants that target serotonin, norepinephrine, or dopamine. That shared mechanism is also why the IV ketamine vs Spravato comparison comes up so frequently for patients with treatment-resistant depression. They are related compounds working through related pathways, but they are not interchangeable, and the clinical, regulatory, and practical differences between them are significant.

FDA Status: The Single Most Important Difference in IV Ketamine vs Spravato

Nothing in the IV ketamine vs Spravato comparison matters more than the regulatory distinction, and it must be stated precisely.

Spravato is FDA-approved for two specific indications only:

1. Treatment-resistant depression (TRD) in adults, used alongside an oral antidepressant
2. Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior

Those are the only two conditions for which Spravato carries FDA approval. It is not approved for anxiety, PTSD, chronic pain, OCD, or any other condition. Any provider or source claiming otherwise is providing inaccurate information.

IV ketamine infusion therapy is off-label for every psychiatric and pain indication, including depression, anxiety, PTSD, and chronic pain. The FDA has not approved IV ketamine for any of these uses. Off-label prescribing by a licensed clinician is legal and widely practiced in medicine, and a substantial and growing body of published research continues to examine IV ketamine’s potential in these areas. But the off-label status must be communicated clearly, and at Allay Health and Wellness, it always is.

This regulatory distinction is not just a technical detail. It directly determines insurance coverage, the clinical protocols that govern administration, and the level of evidence that has been reviewed by regulators. When patients understand this layer of the IV ketamine vs Spravato comparison, they are in a much better position to have an honest clinical conversation.

IV Ketamine vs Esketamine: How Treatment Is Administered

The administration difference in IV ketamine vs esketamine is significant and shapes the treatment experience in practical ways.

IV ketamine is administered intravenously through a line placed in your arm. The infusion is delivered slowly over approximately 40 to 60 minutes while you remain seated or reclining in a private clinical room. A licensed clinician is present and monitoring your vital signs throughout the entire session. You remain conscious but will likely experience a dissociative state, which is an expected and temporary effect of the medication.

Spravato is self-administered as a nasal spray by the patient under clinical supervision. You apply the spray yourself while a licensed clinician observes. After administration, you remain in the certified clinical setting for a mandatory minimum two-hour observation period during which blood pressure, heart rate, oxygen levels, and overall response are monitored continuously.

Neither treatment is available for home use. This is non-negotiable for Spravato under the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program, and it is the clinical standard at Allay Health and Wellness for IV ketamine as well. A licensed clinician is present for every session of both treatments.

Treatment Schedules: IV Ketamine vs Spravato

Treatment timing is an important practical factor in the IV ketamine vs Spravato comparison because both options require planning around clinic visits, transportation, work, and recovery time. IV ketamine commonly begins with a standard initial course of six infusions over two to three weeks. After that, some patients may discuss maintenance infusions based on clinical response, symptom changes, and provider recommendations.

Spravato follows a more structured FDA-approved schedule. The induction phase of therapy usually involves two sessions per week for four weeks, followed by a maintenance phase that may taper to once weekly or once every two weeks, depending on individual response. Both treatments require medical supervision, monitoring, and a responsible adult to provide transportation home after each session. Patients comparing IV ketamine vs Spravato should understand that the early treatment period can be time-intensive, so planning ahead for appointments, rest, and travel is important.

Side Effects: What to Expect from Each

The side-effect comparison in IV ketamine vs Spravato is important to understand in full before committing to either treatment.

Both share a common set of expected side effects related to their shared mechanism:

• Dissociation: A temporary altered state involving changes in perception of time, space, or self. This is an expected and well-documented effect of both IV ketamine and Spravato at therapeutic doses. It is monitored by clinical staff throughout every session.
• Sedation: Both treatments produce sedation. This is why patients cannot drive on the day of any session.
• Blood pressure changes: Temporary increases in blood pressure occur during both IV ketamine infusions and Spravato sessions. Vital signs are monitored before, during, and after every session at Allay Health and Wellness.
• Nausea and dizziness: Generally mild and typically resolving within the observation period.
• Psychological effects: Some patients experience anxiety, unusual perceptions, or emotional intensity during the session. Clinical staff are present throughout to provide support.

There are also side-effect considerations that are more specific to each treatment in this IV ketamine vs Spravato comparison:

For Spravato, the REMS program requirements mean that the two-hour post-dose observation is not optional. It exists specifically because of the dissociation and blood pressure effects. Spravato also cannot be taken home under any circumstances.

For IV ketamine, which is administered intravenously rather than intranasally, the infusion rate and dose can be adjusted by the clinician in real time based on how you are responding. This offers a degree of individualized titration that the nasal spray format does not provide in the same way.

Regarding controlled substance status: ketamine is a Schedule III controlled substance under federal law. Dependency risk at supervised therapeutic doses in a licensed clinical setting is considered low but is not zero. This is discussed with every patient during intake.

Insurance Coverage: A Key Difference in IV Ketamine vs Spravato

Insurance is one of the clearest practical differences in the IV ketamine vs Spravato comparison. Spravato may be eligible for coverage through Medicare, Cigna, United Healthcare, and Aetna when it is prescribed for FDA-approved indications and medical necessity is properly documented. Because Spravato has FDA approval for specific depression-related conditions, insurers may review it differently from off-label treatments.

IV ketamine is generally not covered by most insurance plans when used for depression, anxiety, PTSD, or chronic pain because those uses are off-label. At Allay Health and Wellness, our team verifies benefits before treatment begins, explains expected costs, and helps patients understand what their plan may or may not cover. Coverage is never guaranteed and depends on diagnosis, documentation, prior authorization rules, and individual plan terms. Our team also assists with preauthorization, benefit verification, and appeals when appropriate, helping patients compare IV ketamine vs Spravato with clearer financial expectations.

Which Conditions Each Treats: A Critical Distinction in IV Ketamine vs Spravato

This is the part of the IV ketamine vs Spravato comparison where the most confusion exists online, and where clinical accuracy matters most.

Spravato treats only two conditions, as described by its FDA-approved indications. Treatment-resistant depression and MDD with acute suicidal ideation or behavior. That is the complete list. Spravato is not used at Allay Health and Wellness for PTSD, anxiety, chronic pain, OCD, or any other indication. Any source suggesting otherwise is not being accurate.

IV ketamine is used off-label for a broader range of conditions that continue to be examined in clinical research. At Allay Health and Wellness, off-label IV ketamine is evaluated for:

• Treatment-resistant depression: IV ketamine may be evaluated for patients who have not responded adequately to standard antidepressants, are not eligible for Spravato, or prefer IV treatment for depression after clinical review.
• Generalized anxiety disorder: IV ketamine may be considered when anxiety symptoms remain difficult to manage after standard treatments, but eligibility depends on diagnosis, treatment history, safety factors, and clinical judgment.
• PTSD: IV ketamine may be evaluated for PTSD when symptoms persist despite standard care. Research is still developing, and treatment decisions require careful review by a licensed clinician.
• Chronic pain: IV ketamine may be considered for certain chronic pain conditions, including neuropathic pain, CRPS, fibromyalgia, and migraines, when clinical evaluation supports its use and safety.

None of these off-label uses carries an FDA approval, and individual responses vary. No specific outcome is guaranteed for any of them.

Who Is a Candidate for Each

Candidacy for IV ketamine vs Spravato is not identical, and the clinical evaluation for each takes different factors into account.

Spravato candidates generally need to have a documented diagnosis of treatment-resistant depression, a record of inadequate response to at least two oral antidepressants at adequate doses and durations, and a willingness to continue an oral antidepressant alongside Spravato, since the FDA-approved indication requires concurrent use. Certain medical contraindications, including uncontrolled hypertension, history of aneurysmal vascular disease, and active psychosis, must also be assessed.

IV ketamine candidates include patients with treatment-resistant depression who may not meet Spravato criteria, as well as patients with anxiety, PTSD, or chronic pain conditions that have not responded to standard treatments. Candidacy for therapy is determined by a full clinical evaluation that covers diagnosis, prior treatment history, cardiovascular health, current medications, and substance use history.

For both, a history of substance use disorders is evaluated carefully because ketamine is a Schedule III controlled substance. It does not automatically disqualify a patient, but it is a significant clinical factor.

Why Integration Matters with IV Ketamine and Spravato

When comparing IV ketamine vs Spravato, it is important to remember that neither treatment is intended to function as a standalone solution. Both are most effective when incorporated into a broader treatment strategy developed by a licensed clinician. Depending on the patient’s diagnosis and individual needs, that strategy may include psychotherapy, medication management, lifestyle changes, and regular follow-up appointments. At Allay Health and Wellness, treatment planning focuses on comprehensive and long-term mental health support rather than simply completing a course of medication or infusions. This approach helps patients build a comprehensive care plan that extends beyond individual treatment sessions.

For patients receiving IV ketamine, ketamine assisted therapy may be recommended as part of the treatment process. Preparation sessions help patients understand what to expect before treatment, while integration sessions provide an opportunity to discuss thoughts, emotions, or experiences that arise afterward. This support can be especially valuable for individuals living with depression, PTSD, or complex trauma histories. Although Spravato follows a different FDA-approved treatment pathway, ongoing therapy and clinical follow-up remain equally important.

Why Choose Allay Health and Wellness When Comparing IV Ketamine and Spravato?

Choosing between IV ketamine vs Spravato involves more than comparing medications. It requires guidance from experienced clinicians who understand the differences in FDA approval, treatment protocols, monitoring requirements, insurance considerations, and patient eligibility. At Allay Health and Wellness, every recommendation begins with a comprehensive evaluation rather than assuming one treatment is appropriate for everyone. Our clinical team reviews diagnosis, treatment history, current medications, medical conditions, and personal goals before discussing available options, helping patients make informed decisions based on evidence and safety rather than marketing claims.

For more than eight years, Allay Health and Wellness has served patients throughout South Florida with individualized mental health care. Our multidisciplinary team includes Katy Redfield, APRN, Co-Founder and Program Director; Nicholas Marino, MBA, Co-Founder and CEO; Roland Verfaillie, Ph.D., Clinical Director with more than 30 years of mental health experience; and Daniel Cartledge, M.D., consultant and double board-certified in pain management and physical medicine and rehabilitation. Patients comparing IV ketamine vs Spravato receive transparent information about potential benefits, known risks, monitoring requirements, and realistic expectations.

FAQs about IV Ketamine vs Spravato

Q1. Is IV ketamine or Spravato better for treatment-resistant depression?
There is no universal answer. Spravato is FDA-approved for treatment-resistant depression and may have insurance pathways. IV ketamine is off-label for depression. A clinician should evaluate diagnosis, history, coverage, and safety factors.

Q2. Can I receive both IV ketamine and Spravato?
Not at the same time. Your clinician will recommend one approach based on your diagnosis, eligibility, medication history, and treatment goals. If the response is limited, other options may be discussed later.

Q3. Why does Spravato require an oral antidepressant?
Spravato’s FDA-approved indication for treatment-resistant depression requires use with an oral antidepressant. IV ketamine protocols differ because IV ketamine for depression is off-label and evaluated case by case.

Q4. Is dissociation different with IV ketamine vs Spravato?
Both may cause temporary dissociation. IV ketamine may feel different because it is administered intravenously, while Spravato is intranasal. Individual experiences vary, and both require clinical monitoring.

Q5. Does Spravato work faster than IV ketamine?
Both treatments have been studied for relatively rapid effects compared with traditional antidepressants. Direct comparisons are limited. Response timelines vary by patient, and no specific result is guaranteed.

Q6. Will insurance cover IV ketamine if Spravato is denied?
Usually not. Off-label IV ketamine for depression is generally not covered by most insurance plans. A Spravato denial does not automatically create coverage for IV ketamine.

Q7. Is Spravato available for PTSD or anxiety?
No. Spravato is FDA-approved only for specific depression-related indications. It is not approved for PTSD, anxiety, chronic pain, or other conditions outside its approved labeling.

Q8. How do I know which option to ask about?
Bring your diagnosis records, medication history, current medications, and insurance information. Your clinician can review your case and explain whether IV ketamine, Spravato, or another option may be appropriate.

Schedule a Consultation at Allay Health and Wellness

If you are ready to have a clear, honest clinical conversation about IV ketamine vs Spravato and which may be appropriate for your situation, Allay Health and Wellness is ready to help.

Allay Health and Wellness

11000 Prosperity Farms Rd, Suite 101
Palm Beach Gardens, FL 33410

Phone: (561) 421-6444
Email: [email protected]

Contact us to request a free consultation. We serve patients from West Palm Beach, Jupiter, North Palm Beach, Riviera Beach, Royal Palm Beach, Lake Park, Palm Springs, Juno Beach, Stuart, Boca Raton, Delray Beach, Deerfield Beach, and communities across Palm Beach and Broward Counties.

Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice. IV ketamine is an off-label treatment for certain conditions, while Spravato is FDA-approved only for specific depression-related indications. Individual outcomes vary. Treatment is provided only after evaluation by a licensed clinician.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness